Health
The GLP-1 Era: How Weight-Loss Drugs Changed Us
Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024
Loading
Search
Results
60 stories for“emerging markets”
FilterAll 60Business 16Latest Trends 11Crypto 9Health 7Fashion 4Technology 4Diving 3Travel 3Design 1Lifestyle 1Sports 1
Health
Yoga Works for Back Pain, Slightly, and Sends About Seventeen People per Hundred Thousand to Hospital
A Cochrane review of twenty-one trials found yoga probably better than no exercise for chronic low back pain, with small improvements. Emergency department data shows injury rates rising, most steeply among people over sixty-five.
Sep 4, 2026
Health
Global Road Deaths Fell 21%, but the Map Is Unequal
WHO’s new figures show real progress despite a billion more vehicles, while poorer countries and vulnerable road users remain on the wrong side of the decline.
Jul 22, 2026
Health
Ashwagandha Has Good Trial Data for Stress and a Growing File of Liver Injury Reports
The most popular Ayurvedic herb in the world looks reassuring in clinical trials and much less so in hepatology case series. A systematic review has identified thirty-seven cases of ashwagandha-associated liver injury.
Sep 4, 2026
Health
Sleep Economy: Tracking, Hacking, Buying Rest
The sleep industry hits $585 billion as Americans invest in mattresses, trackers, and supplements to optimize rest. But obsessing over sleep data might actually backfire.
Feb 15, 2024
Health
Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet
TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026
Health
Retatrutide's Third Receptor Is the Hormone That Raises Blood Sugar. Adding It On Purpose Is the Whole Idea
Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026
